Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-uPAR/PLAUR Antibody (7R378) is a Mouse antibody targeting uPAR/PLAUR. Anti-uPAR/PLAUR Antibody (7R378) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $198 | 7-10 days |
Description | Antibody Type: Mouse Monoclonal Application: FCM Reactivity: Human |
Alias | URKR, U-PAR, UPAR, plasminogen activator, urokinase receptor, CD87 |
Ig Type | Mouse IgG1 |
Clone | 7R378 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human UPAR(CD87) expression on human whole blood granulocytes. Cells were stained with purified anti-Human UPAR(CD87), then a FITC-conjugated second step antibody. The histogram were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. |
Application | FCM |
Recommended Dose | FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human PLAUR / CD87 (rh PLAUR / CD87; TMPY-02141; Q03405-1; Met1-Arg303). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma. |
Conjucates | Unconjugated |
Others Formats | APC/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Protein: Human PLAUR / CD87 protein (TMPY-02141) |
Antigen Species | Human |
Biology Area | Serine Proteases and Regulators |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.